Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P61964

UPID:
WDR5_HUMAN

ALTERNATIVE NAMES:
BMP2-induced 3-kb gene protein

ALTERNATIVE UPACC:
P61964; Q91VA5; Q9NWX7; Q9UGP9

BACKGROUND:
The WD repeat-containing protein 5, known for its alternative name BMP2-induced 3-kb gene protein, contributes significantly to the epigenetic mechanisms governing gene expression. It facilitates the trimethylation of histone H3 at 'Lys-4', a marker for transcriptional activation, and participates in the acetylation of nucleosomal histone H4. Its function extends to regulating osteoblast differentiation and enhancing the activity of several histone methyltransferases, indicating its broad role in cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of WD repeat-containing protein 5 unveils potential pathways for therapeutic development. Its central role in histone modification and gene expression regulation makes it a promising candidate for targeting in diseases where these processes are altered, offering a new horizon for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.